Every 8-K that Johnson & Johnson (JNJ) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow JNJ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JNJ filings page.
Johnson & Johnson announced that Jennifer Taubert will retire as Executive Vice President, Worldwide Chairman, Innovative Medicine and member of the Executive Committee, effective September 1, 2026, after a career spanning more than 21 years with the company.
Under her leadership, the Innovative Medicine business grew to more than $60 billion in annual revenue. She will be succeeded by Tom Cavanaugh, currently Company Group Chairman, North America, Innovative Medicine, who will become Executive Vice President, Worldwide Chairman, Innovative Medicine and join the Executive Committee as part of a planned leadership transition.
Johnson & Johnson completed the acquisition of Firefly Bio, Inc., a biotechnology company with its proprietary Firelink™ degrader antibody conjugate platform, for $1 billion in cash. The deal is accounted for as an asset acquisition and will result in an in-process research and development charge of approximately $1 billion in the third quarter of 2026. Firefly is expected to dilute adjusted operational earnings per share and adjusted earnings per share by approximately $0.46 in 2026 and approximately $0.08 in 2027.
The company also entered strategic agreements and a collaboration with Sail Biomedicines, involving total initial payments of $785 million, including a $465 million equity investment, up to $140 million in contingent milestone payments, and an exclusive option to acquire Sail for $2.58 billion. Assuming exercise of the option, these agreements are expected to dilute adjusted operational EPS and adjusted EPS by approximately $0.18 in 2026 and approximately $1.28 in 2027. Together, the transactions reduce 2026 adjusted operational EPS guidance by about $0.64 to a range of $10.86–$11.01 (midpoint $10.94) and adjusted EPS to $10.96–$11.11 (midpoint $11.04), and shift adjusted pre-tax operating margin from an expected ~75 bps increase to a ~75 bps decrease versus the prior year, a combined impact of ~150 bps, while maintaining 2026 sales growth guidance.
Johnson & Johnson has agreed in principle to a comprehensive resolution of remaining ovarian talc litigation with plaintiff firms leading the federal Multi-District Litigation and related state cases. The proposed framework is conditioned on participation from at least 95% of remaining claimants, covering approximately 76,000 ovarian talc claims. It provides per-claim payments under a total $5.5 billion commitment, with a first payment of no more than $3 billion in 2027 and no additional payments due before 2028.
The company links this proposal to a recent MDL court ruling on “specific causation,” after which plaintiffs withdrew certain experts and the court ordered them to show why remaining claims should not be dismissed. Johnson & Johnson states it has already resolved about 95% of filed mesothelioma lawsuits, all state consumer protection claims, and all talc-supplier disputes, and that this agreement, if completed, would efficiently conclude 15 years of talc litigation so it can focus on its Innovative Medicine and MedTech businesses.
Johnson & Johnson reported second‑quarter 2026 sales of $25.3 billion, up 6.6% from 2025, with Innovative Medicine up 7.8% and MedTech up 4.5%. Net earnings were $5.53 billion and diluted EPS $2.27, compared with $2.29 a year earlier. On a non‑GAAP basis, adjusted net earnings rose to $7.08 billion and adjusted diluted EPS to $2.90, increases of 5.7% and 4.7%.
For the first six months of 2026, sales reached $49.4 billion, up 8.2%, while GAAP net earnings declined to $10.77 billion and EPS to $4.41. Adjusted diluted EPS for the period was $5.60, up 1.3%. Strong operational performance results in the company increasing 2026 guidance, now estimating reported sales of $100.8–$101.4 billion (midpoint $101.1 billion) and adjusted diluted EPS of $11.60–$11.75 (midpoint $11.68). The release also highlights recent approvals and data for products including TREMFYA, CAPLYTA and the Dual Energy THERMOCOOL SMARTTOUCH SF platform, along with broader Innovative Medicine and MedTech pipeline and investment activity.
Johnson & Johnson reported the results of its 2026 Annual Meeting of Shareholders held on April 23, 2026. Shareholders elected all 12 director nominees to the Board of Directors, with each nominee receiving significantly more votes "For" than "Against."
Investors also approved, on an advisory basis, the company’s executive compensation program described in the 2026 Proxy Statement, and ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal 2026. A shareholder proposal to adopt a policy requiring an independent board chair did not pass, receiving substantially more votes "Against" than "For."
Johnson & Johnson reported strong first-quarter 2026 growth, with reported sales rising 9.9% to $24.1 billion, driven by Innovative Medicine and MedTech. Diluted EPS under GAAP was $2.14, down from $4.54, while adjusted diluted EPS was $2.70, slightly below $2.77 a year earlier.
The company raised its 2026 outlook to estimated reported sales of $100.8 billion and adjusted EPS of $11.55, both implying around 7% growth at the midpoints. The Board also increased the quarterly dividend by 3.1%, from $1.30 to $1.34 per share, for an annual rate of $5.36 and a 64-year streak of consecutive dividend increases.
Johnson & Johnson filed a Form 8-K to share that it has issued a press release announcing its sales and earnings for the fourth quarter and full year ended December 28, 2025. The filing states that the press release is attached as Exhibit 99.1 and covers both quarterly and annual performance.
The company also attached unaudited comparative supplementary sales data and a condensed consolidated statement of earnings for the same periods as Exhibit 99.2. This 8-K centers on making these earnings materials publicly available rather than detailing the specific financial results within the form itself.
Johnson & Johnson filed an 8-K announcing two updates. First, it issued a press release reporting sales and earnings for the third quarter ended September 28, 2025. Second, it announced its intent to separate the Company’s Orthopaedics business.
The filing notes the related exhibits: Exhibit 99.1 contains the Q3 2025 press release and Exhibit 99.2 provides unaudited comparative supplementary sales data and a condensed consolidated statement of earnings for the fiscal third quarter and nine months. Exhibit 99.3 contains the press release about the planned Orthopaedics separation. These disclosures were dated October 14, 2025.